The earnings call reflects a positive sentiment with strong revenue and EBITDA growth, particularly in the On-X and stent graft segments, alongside a significantly improved balance sheet. While there are some challenges from past cybersecurity incidents and slower growth in tissue processing and BioGlue, the overall performance and outlook are favorable.

Company Guidance -

Q3 2025

During the Artivion Second Quarter 2025 Earnings Call, the company reported a strong performance with total constant currency revenue growth of over 14% and adjusted EBITDA growth of 33% year-over-year. The On-X product category saw a 24% revenue increase, while stent graft revenues grew 22%, BioGlue increased by 4%, and tissue processing revenues rose by 3%, all on a constant currency basis. The U.S. market demonstrated exceptional strength, particularly in On-X sales. Artivion's net leverage ratio was reduced to 2.2 from 4.1 in the prior year, following the retirement of convertible notes due in 2025. The company also raised the midpoint of its full-year 2025 revenue guidance, now expecting constant currency growth between 12% and 14%, and adjusted EBITDA in the range of $86 million to $91 million. Key growth drivers include the ongoing U.S. launch of the AMDS following FDA HDE approval, which is tapping into a $150 million annual market opportunity, and the anticipated U.S. pivotal trial for the Arcevo LSA, with IDE approval received in July.

Strong Revenue and EBITDA Growth

Artivion reported total constant currency revenue growth of over 14% and adjusted EBITDA growth of 33% year-over-year for Q2 2025.

Successful On-X Valve Sales

On-X valve revenue increased 24% year-over-year, driven by strong U.S. sales and positive new data, reinforcing market share gains.

Stent Graft Revenue Surge

Stent graft revenues grew 22% on a constant currency basis, primarily due to the U.S. launch of AMDS.

Balance Sheet Strengthening

Artivion significantly reduced net leverage by retiring $100 million of convertible debt, improving the net leverage ratio from 4.1 to 2.2.

Positive AMDS Launch

AMDS revenue showed strong early demand, with a meaningful growth on a sequential basis, tapping into a $150 million market opportunity.

Free Cash Flow Improvement

Free cash flow was $11.7 million in Q2 2025, contributing to the overall financial health of the company.

Artivion (AORT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AORT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.02 / -	-0.05	―	―	―
Aug 07, 2025	2025 (Q2)	>-0.01 / 0.03	-0.05	160.00% (+0.08)
May 05, 2025	2025 (Q1)	-0.12 / -0.01	0.18	-105.56% (-0.19)
Feb 24, 2025	2024 (Q4)	-0.07 / -0.39	-0.1	-290.00% (-0.29)
Nov 07, 2024	2024 (Q3)	-0.06 / -0.05	-0.24	79.17% (+0.19)
Aug 08, 2024	2024 (Q2)	-0.09 / -0.05	-0.08	37.50% (+0.03)
May 06, 2024	2024 (Q1)	-0.12 / 0.18	-0.33	154.55% (+0.51)
Feb 15, 2024	2023 (Q4)	-0.09 / -0.10	0.05	-300.00% (-0.15)
Nov 02, 2023	2023 (Q3)	-0.06 / -0.24	-0.34	29.41% (+0.10)
Aug 03, 2023	2023 (Q2)	-0.06 / -0.08	-0.11	27.27% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AORT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$32.70	$40.95	+25.23%
May 05, 2025	$23.77	$27.42	+15.36%
Feb 24, 2025	$27.85	$25.56	-8.22%
Nov 07, 2024	$28.98	$28.71	-0.93%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Artivion (AORT) report earnings?

Artivion (AORT) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Artivion (AORT) earnings time?

Artivion (AORT) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AORT EPS forecast?

AORT EPS forecast for the fiscal quarter 2025 (Q3) is 0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing